For two decades, "HRT causes cancer" hung over hormone therapy like a fog. The reality that specialists now teach is more precise — and more hopeful — than that headline. The single most important idea is timing: the same therapy carries a different balance of benefit and risk depending on your age and how long it's been since menopause.

The "window of opportunity"

Current guidance from The Menopause Society is that for healthy women younger than 60, or within 10 years of menopause onset, and without contraindications, the benefit-risk balance is favorable for treating bothersome hot flashes and night sweats and for preventing bone loss.¹ This is often called the timing hypothesis or the window of opportunity.

Start much later — more than 10 years past menopause or after age 60 — and the picture shifts: the absolute risks of coronary heart disease, stroke, blood clots (venous thromboembolism), and dementia become more significant, so the balance is less favorable.¹

Why the WHI scared everyone — and what it actually showed

The alarm traces back to the Women's Health Initiative, a large trial whose early results made headlines in the early 2000s. The catch: the average participant was many years past menopause — well outside the window above. Applying those results to a symptomatic 51-year-old overstated her risks. The modern reappraisal, reflected in both The Menopause Society and NICE guidance, is why the conversation has changed.¹²

Risk depends on how it's given

This is the nuance that blanket warnings erase. The risks differ by type, dose, duration, route of administration, timing, and whether a progestogen is used.¹ For example:

• Route matters. Starting within the window carries lower complication risk, and cardiovascular risk is not significantly increased in that group; transdermal (patch/gel) routes are often preferred because they may carry lower clot and stroke risk than oral estrogen.³
• Estrogen-alone vs. combined differ for breast cancer. The small increase in breast-cancer risk is mainly associated with estrogen-plus-progestogen therapy and rises with duration of use; estrogen-alone carries a different, lower profile. Crucially, the increase is best understood in absolute terms — it amounts to well under one extra breast-cancer case per 1,000 women per year — and the association attenuates after stopping.⁴

The honest summary

Hormone therapy can raise the chance of blood clots, stroke, and (with combined therapy) breast cancer, and certain types carry more risk than others — these are real and worth discussing. But for the right woman at the right time, the benefits for symptoms and bone can outweigh those risks.¹ That "for whom, and when" is exactly why the next article is about the conversation with your doctor.

This article is general educational information, not medical advice, and it necessarily simplifies a complex, evolving evidence base. Risk and benefit are individual. Discuss your specific history with a qualified clinician before making any decision.